Samsung C&T announced Thursday that its Life Science Fund, established in collaboration with Samsung Biologics, Samsung Bioepis and Samsung Venture Investment, will invest $10 million in C2N Diagnostics, a US-based Alzheimer’s testing company.
C2N specializes in analyzing protein biomarkers — biological indicators used to track disease progression and drug responses — found in extremely low concentrations in the blood. Leveraging this technology, the company has developed a blood test for diagnosing Alzheimer’s disease and has participated in global clinical trials for Alzheimer’s treatments and other central nervous system disorders.
C2N’s blood test provides a safer and more cost-effective alternative to traditional diagnostic methods, such as amyloid PET-CT scans and cerebrospinal fluid tests. The test enables precise measurement of multiple Alzheimer’s-related proteins, including amyloid-beta, making Alzheimer’s diagnoses more accessible and convenient.
The company plans to seek FDA approval for its test within this year. C2N CEO Joel Braunstein said the investment will support global expansion efforts.
“C2N Diagnostics has the potential to lead pharmaceutical research support and related services,” said Kim Jae-woo, vice president of Samsung C&T’s life science division. “This investment secures Samsung’s foothold in the sector.”
The Life Science Fund, managed by Samsung Venture Investment, was established with 240 billion won ($180 million) to foster next-generation biotechnologies. Previous investments include Araris Biotech and AimedBio, which specialize in antibody-drug conjugates, and Generate Biomedicines, which develops protein-based biopharmaceuticals using machine learning.
hyelimchung@heraldcorp.com
